menu
    • menu
    [{"orgOrder":0,"company":"Evive Biotech","sponsor":"Peking University Cancer Hospital & Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Recombinant Anti-CD19\/CD3 Bispecific Antibody","moa":"CD19\/CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Evive Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evive Biotech \/ Peking University Cancer Hospital & Institute","highestDevelopmentStatusID":"6","companyTruncated":"Evive Biotech \/ Peking University Cancer Hospital & Institute"},{"orgOrder":0,"company":"Evive Biotech","sponsor":"Aurobindo Pharma Limited","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"INDIA","productType":"Protein","year":"2022","type":"Licensing Agreement","leadProduct":"Benegrastim","moa":"Granulocyte colony stimulating factor receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Evive Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evive Biotech \/ Evive Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Evive Biotech \/ Evive Biotech"},{"orgOrder":0,"company":"Evive Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"F-627","moa":"Granulocyte colony stimulating factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Evive Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evive Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Evive Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Evive Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"F-627","moa":"Granulocyte colony stimulating factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Evive Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evive Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Evive Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Evive Biotech","sponsor":"Fudan University","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"F-627","moa":"Granulocyte colony stimulating factor receptor","graph1":"Hematology","graph2":"Phase II","graph3":"Evive Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evive Biotech \/ Fudan University","highestDevelopmentStatusID":"8","companyTruncated":"Evive Biotech \/ Fudan University"},{"orgOrder":0,"company":"Evive Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"F-627","moa":"Granulocyte colony stimulating factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Evive Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evive Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Evive Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Evive Biotech","sponsor":"Fudan University | Affiliated Cancer Hospital & Institute of Guangzhou Medical University | Nanfang Hospital, Southern Medical University | The Affiliated Hospital of Qingdao University | Tongji Hospital | The Affiliated Tumor Hospital of Nantong Universi","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"F-627","moa":"Granulocyte colony stimulating factor receptor","graph1":"Hematology","graph2":"Phase II","graph3":"Evive Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evive Biotech \/ Fudan University | Affiliated Cancer Hospital & Institute of Guangzhou Medical University | Nanfang Hospital, Southern Medical University | The Affiliated Hospital of Qingdao University | Tongji Hospital | The Affiliated Tumor Hospital of Nantong Universi","highestDevelopmentStatusID":"8","companyTruncated":"Evive Biotech \/ Fudan University | Affiliated Cancer Hospital & Institute of Guangzhou Medical University | Nanfang Hospital, Southern Medical University | The Affiliated Hospital of Qingdao University | Tongji Hospital | The Affiliated Tumor Hospital of Nantong Universi"},{"orgOrder":0,"company":"Evive Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"F-627","moa":"Granulocyte colony stimulating factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Evive Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evive Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Evive Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Evive Biotech","sponsor":"Fudan University | Sun Yat-sen University","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"F-627","moa":"Granulocyte colony stimulating factor receptor","graph1":"Hematology","graph2":"Phase II","graph3":"Evive Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evive Biotech \/ Fudan University | Sun Yat-sen University","highestDevelopmentStatusID":"8","companyTruncated":"Evive Biotech \/ Fudan University | Sun Yat-sen University"},{"orgOrder":0,"company":"Evive Biotech","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"F-652","moa":"IL22 Receptor","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Evive Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Evive Biotech \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Evive Biotech \/ Memorial Sloan Kettering Cancer Center"},{"orgOrder":0,"company":"Evive Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"F-652","moa":"IL22 Receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Evive Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evive Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Evive Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Evive Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"F-652","moa":"IL22 Receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Evive Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evive Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Evive Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Evive Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Efbemalenograstim Alpha","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Evive Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evive Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Evive Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Evive Biotech","sponsor":"Nona Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Evive Biotech","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evive Biotech \/ Nona Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"Evive Biotech \/ Nona Biosciences"}]

    Find Clinical Drug Pipeline Developments & Deals by Evive Biotech

    Menu

    Evive Biotech

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Evive Biotech

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Evive Biotech

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Study Phase : Discovery

                            Sponsor : Nona Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Nona Biosciences Announces Collaboration with Evive Biotech to Accelerate Antibody Discovery

                            Details : The collaboration aims to accelerate the process of antibody discovery and drug development based on the Harbour Mice® antibody technology platform of Nona Biosciences.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            December 10, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery

                            Sponsor : Nona Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Evive Biotech

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Evive Biotech

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Benegrastim

                            Therapeutic Area : Hematology

                            Study Phase : Phase III

                            Recipient : Aurobindo Pharma Limited

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Aurobindo Unit, Evive Biotech Ink Licensing Pact to Commercialise CIN Treatment Product in US

                            Details : Under the terms of the agreement, Evive will be responsible for the ongoing development, manufacturing, registration, and supply of Ryzneuta (benegrastim), while Acrotech will use its sales and commercialisation capabilities to market and distribute the ...

                            Product Name : Ryzneuta

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            November 23, 2022

                            Lead Product(s) : Benegrastim

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase III

                            Recipient : Aurobindo Pharma Limited

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Evive Biotech

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Evive Biotech

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : F-652

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of F-652 in Subjects With Corona Virus Disease 2019 (COVID-19) Pneumonia

                            Details : F-652 is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            January 25, 2022

                            Lead Product(s) : F-652

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Evive Biotech

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Evive Biotech

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : F-652

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of F-652 (IL-22:IgG2 Fusion Protein) in Patients With Moderate to Severe COVID-19

                            Details : F-652 is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            August 04, 2020

                            Lead Product(s) : F-652

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Evive Biotech

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Evive Biotech

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Efbemalenograstim Alpha

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evive Biotech meets Promising Results at Global Ph III Trial for Neutropenia Treatment

                            Details : Safety and efficacy endpoints met successfully in pivotal trial for F-627 (efbemalenograstim alfa), a novel long-acting G-CSF . F-627 has proven that it is at least as efficacious and safe as NEULASTA®, which is the current standard of care.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            July 08, 2020

                            Lead Product(s) : Efbemalenograstim Alpha

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Evive Biotech

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Evive Biotech

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : F-627

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Compare the Efficacy and Safety of F-627 and GRAN®

                            Details : F-627 is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Breast Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            November 22, 2019

                            Lead Product(s) : F-627

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Evive Biotech

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Evive Biotech

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Recombinant Anti-CD19/CD3 Bispecific Antibody

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Peking University Cancer Hospital & Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of A-319 in Patients With Relapsed or Refractory B-cell Lymphoma

                            Details : Recombinant Anti-CD19/CD3 Bispecific Antibody is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lymphoma, B-Cell.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            August 14, 2019

                            Lead Product(s) : Recombinant Anti-CD19/CD3 Bispecific Antibody

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Peking University Cancer Hospital & Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Evive Biotech

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Evive Biotech

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : F-627

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

                            Details : F-627 is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Breast Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            August 17, 2017

                            Lead Product(s) : F-627

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Evive Biotech

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Evive Biotech

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : F-627

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

                            Details : F-627 is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Breast Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            August 19, 2016

                            Lead Product(s) : F-627

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Evive Biotech

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Evive Biotech

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : F-627

                            Therapeutic Area : Hematology

                            Study Phase : Phase I

                            Sponsor : Fudan University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

                            Details : F-627 is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neutropenia.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            August 19, 2015

                            Lead Product(s) : F-627

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase I

                            Sponsor : Fudan University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth